Palvella Therapeutics, Inc. (PVLA): Net Income
-$41.72M
Year ended 2025-12-31
-$61.70M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$41.72M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$17.43M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $18.69M | n/c | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$33.28M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | -$45.74M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$37.23M | n/m | 2022-03-02, From 2020-01-01 |
| 2019-12-31 | -$25.47M | n/m | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | -$26.75M | n/m | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | -$17.65M | n/m | 2019-03-18, From 2017-01-01 |
| 2016-12-31 | -$22.80M | n/m | 2018-03-15, From 2016-01-01 |
| 2015-12-31 | -$14.06M | n/m | 2017-03-30, From 2015-01-01 |
| 2014-12-31 | -$9.85M | n/m | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | $66.2K | n/a | 2015-03-30, From 2013-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | -$41.72M | n/m |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | -$14.74M | n/m |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | -$101.69M | n/m |
| Scynexis Inc (SCYX) | 2025-12-31 | -$8.61M | n/m |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | -$20.43M | n/m |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | -$40.95M | n/m |
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | -$61.80M | n/m |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | -$32.77M | n/m |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $29.82M | n/m |
Compare PVLA, PRPH, ALXO, SCYX side by side · Screen every company in Pharmaceutical Preparations ↗